Verona Pharma
Aggregated from S&P 500 earnings calls
Total Mentions
3
Companies
1
Sentiment
BULLISH 1
Mentions by Company
Merck & Co. Inc.Q3-2025
3×BULLISH
“Completed Acquisition of Verona Pharma and Its First-In-Class COPD Maintenance Treatment for Adults, OHTUVAYRE, in October”
“Estimated negative impact of $0.04 per share related to the acquisition of Verona Pharma”